Clinical jobs provider Parexel has addressed its record performance in the fiscal year that ended on June 30th.
The biopharmaceutical services company reported revenue of $1.2 billion (£744.9 million) in the 12-month period, which was achieved after a record-breaking fourth quarter.
Overall, the firm's yearly results have met expectations and supported its plans to continue to invest in growth throughout 2011-12.
Chairman and chief executive Josef von Rickenbach claimed the high figures were brought about by increasing demand from the emerging biopharma market.
"The year's new business and backlog results clearly demonstrate that Parexel is a partner of choice for many clients," he added.
Last month, an independent study published by Industry Standard Research showed that the company is ranked highest among large clinical research organisations.